OncoMark has an active Research & Development programme designed to feed new innovative products into our pipeline.
OncoMasTR signature for other human cancers
The application of the OncoMasTR signature to a number of human cancers has been evaluated through analysis of publicly available transcriptomic datasets and this has revealed significant prognostic capability for the OncoMasTR panel. The human cancers evaluated include colorectal, prostate, bladder, melanoma and multiple myeloma. The OncoMasTR patent contains claims for application of the OncoMasTR panel in all major human cancers.
OncoMasTR signature as a predictive biomarker for CDK4/6 inhibitors
A major opportunity exists for the application of the OncoMasTR panel as a predictive biomarker for the latest drug therapy for metastatic breast cancer, CDK4/6 inhibitors. Drugs such as Palbociclib and Ribociclib, recently approved by the FDA and now entering routine clinical use, are extremely effective but a significant proportion of patients will not benefit from the treatment. Currently, no test exists to identify those that will or will not benefit. With a course of treatment costing in the region of $80,000 the potential benefit of an accurate biomarker to address this issue is enormous. This pipeline project is being carried out in conjunction with Prof. John Crown, Medical Oncologist at St. Vincent’s University Hospital, and a co-investigator on the Palbociclib Clinical Trial.
OncoMark is also participating in a novel research programme to identify and evaluate new Dynamic Biomarkers with applications in Breast cancer. Current molecular diagnostics used in clinical decision-making are significantly limited by the static nature of the single time-point traditionally utilised for analysis (most commonly, the original primary tumour). There is increasing interest to use on-treatment tissue to provide a dynamic and more pertinent sample for assessment of therapeutic response. The overall goal of this pipeline programme is to take advantage of the novel concept of dynamic biomarkers, as tools to better understand the molecular basis of resistance to targeted therapies, and to apply these for more effective patient stratification.